Jordan E. Pinsker

Pediatric Endocrinology

2219 Bath Street
William Sansum Diabetes Center
Santa Barbara, CA 93105

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures.

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures.

Journal: The American journal of managed care

Published: August 25, 2026

First Use of Control-IQ+ Technology in Newly Indicated Populations.

First Use of Control-IQ+ Technology in Newly Indicated Populations.

Journal: Diabetes technology & therapeutics

Published: June 10, 2026

Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.

Real-world outcomes using the Tandem Mobi insulin pump with Control-IQ+ technology and Dexcom G7.

Journal: Diabetic medicine : a journal of the British Diabetic Association

Published: April 17, 2026

Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes.

Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes.

Journal: Diabetes technology & therapeutics

Published: January 23, 2026

HEDIS glycemic goal achieved using control-IQ Technology.

HEDIS glycemic goal achieved using control-IQ Technology.

Journal: The American journal of managed care

Published: January 09, 2026

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.

Journal: Obstetrical & gynecological survey

Published: December 30, 2025

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: December 30, 2025

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Journal: Diabetes, obesity & metabolism

Published: December 12, 2025

Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes.

Simplified Meal Bolus Strategies with Control-IQ+ Automated Insulin Delivery Are Safe and Effective in Adults with Type 2 Diabetes.

Journal: Diabetes technology & therapeutics

Published: November 20, 2025

Fully Closed-Loop Insulin Delivery with High-Carbohydrate and High-Fat Meals Using the Tandem Freedom System.

Fully Closed-Loop Insulin Delivery with High-Carbohydrate and High-Fat Meals Using the Tandem Freedom System.

Journal: Journal of diabetes science and technology

Published: November 14, 2025

Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies.

Automated Insulin Delivery Is Beneficial in Adults With Insulin-Treated Type 2 Diabetes With and Without GAD65 Antibodies.

Journal: Diabetes care

Published: August 20, 2025

A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes.

A Multicenter Study of an Investigational Extended Wear Insulin Infusion Set in Adults with Type 1 Diabetes.

Journal: Diabetes technology & therapeutics

Published: August 08, 2025

Showing 1-12 of 108

Last Updated: 09/26/2026